Deflazacort 6 mg
| Composition | Deflazacort 6 mg |
|---|---|
| Packing | 10x10 Alu Alu |
| MRP | ₹ 1800 |
| Dosage Form | Tablets |
Ziacort-6 Tablet contains Deflazacort 6 mg, a modern corticosteroid derived from prednisolone that offers potent anti-inflammatory and immunosuppressive activity. Deflazacort is distinguished by its relatively lower impact on calcium and bone metabolism compared to other corticosteroids at equivalent anti-inflammatory doses, which is clinically relevant when prolonged steroid therapy is required.
Ziacort-6 is used across a wide range of inflammatory, autoimmune, and allergic conditions. Doctors prescribe it when the anti-inflammatory power of a corticosteroid is needed, with the benefit of a somewhat more favourable bone and metabolic side effect profile for many patients.
This medicine is commonly used for:
Deflazacort is indicated for conditions requiring systemic corticosteroid therapy including rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel conditions, nephrotic syndrome, severe asthma, allergic and dermatological disorders, and as an alternative corticosteroid in Duchenne muscular dystrophy where it is associated with a lower weight-gain profile compared to prednisolone.
Deflazacort is a corticosteroid — a type of medicine that works like the body's natural anti-inflammatory hormone cortisol. It calms down an overactive immune system and reduces inflammation in the body. This helps relieve swelling, pain, and tissue damage in a wide range of inflammatory conditions.
Deflazacort is a prodrug rapidly converted to its active metabolite, 21-desacetyldeflazacort, which binds to the intracellular glucocorticoid receptor (GR). The drug-receptor complex translocates to the nucleus where it acts as a transcription factor — upregulating anti-inflammatory genes (lipocortin-1, interleukin-10) and downregulating pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) via transrepression of NF-kB and AP-1. Relative to prednisolone, deflazacort demonstrates a more favourable calcium-phosphorus metabolism profile, resulting in less calcium loss from bone at equivalent anti-inflammatory doses.
Deflazacort was originally developed to provide effective corticosteroid therapy with a reduced impact on bone — a key concern with long-term steroid use. In Duchenne muscular dystrophy, it is preferred over prednisolone in some treatment guidelines because it causes less weight gain and may have a slightly better side-effect profile in that specific setting.
Ziacort-6 should be taken exactly as prescribed by your doctor, usually in the morning with food to reduce stomach upset and to align with the body's natural cortisol cycle. Never stop this medicine suddenly — your doctor will guide you on how to gradually reduce the dose when treatment is no longer needed.
Always follow the dosage and schedule advised by your doctor — this is general guidance only.
As with all corticosteroids, Ziacort-6 may cause side effects with prolonged use, including increased appetite, weight gain, mood changes, fluid retention, raised blood sugar levels, and increased susceptibility to infections. Short-term use at low doses is generally better tolerated. Tell your doctor if any side effect is severe or persistent.
All steroids are the same and equally harmful.
Different corticosteroids have distinct profiles. Deflazacort in Ziacort-6 has a relatively more favourable calcium-metabolism and weight-gain profile compared to prednisolone at equivalent doses. When used appropriately under medical supervision, the benefits can outweigh the risks.
You can stop taking steroid tablets as soon as you feel better.
Corticosteroids must never be stopped abruptly after a course of treatment, as this can cause adrenal insufficiency — a dangerous drop in the body's stress hormones. Always follow your doctor's tapering schedule.